TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30643112
Drug: Pressurized intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin 92 mg/m² or cisplatin 7.5 mg/m² and doxorubicin 1.5 mg/m², repeated every 6 weeks
Study: 30644585
Drug: Cangrelor as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor as a bridge therapy
Study: 30644817
Drug: Focused ultrasound-mediated
Normalized name: carbinoxamine maleate Oral Solution [Pediatex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused ultrasound-mediated hyperthermia for targeted drug delivery
Study: 30648126
Drug: Dalbavancin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin (1500 mg IV on days 1 and 8)
Study: 30648126
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) for osteomyelitis (oral or IV) per investigator judgment for 4-6 weeks
Study: 30648632
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/day individualized schedule
Study: 30648932
Drug: PCV13 (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 (first dose)
Study: 30650259
Drug: Plazomicin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plazomicin (15 mg/kg administered by 30-minute intravenous infusion)
Study: 30650259
Drug: Plazomicin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plazomicin (20 mg/kg administered by 30-minute intravenous infusion)
Study: 30651126
Drug: Avelumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (10 mg/kg)
Study: 30654137
Drug: Plerixafor (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (240 μg/kg s.c.) administered before conditioning chemotherapy (fludarabine and busulfan) for 1 to 4 days depending on the cohort.
Study: 30656283
Drug: Prophylactic rFIXFc
Normalized name: rFIXFc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic rFIXFc with a ≥14-day dosing interval
Study: 30656479
Drug: Pressure-volume curve-guided
Normalized name: Curae
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pressure-volume curve-guided PEEP titration
Study: 30657223
Drug: Aflibercept (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (4 mg/kg) plus FOLFIRI administered every 2 weeks
Study: 30657914
Drug: Dairy intake
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy intake (100 g/d increase)
Study: 30657914
Drug: Fruit and
Normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit and vegetable intake (100 g/d increase)
Study: 30657926
Drug: Plasma cotinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma cotinine (per 1 ng/mL)
Study: 30658128
Drug: 9-valent HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent HPV vaccine
Study: 30658992
Drug: Pediatric ALL
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pediatric ALL regimen administered by adult treatment teams
Study: 30660511
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks up to four times)
Study: 30660617
Drug: Grazoprevir 100
Normalized name: grazoprevir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 100 mg plus Elbasvir 50 mg (8 weeks treatment)
Study: 30661177
Drug: Danvatirsen 3
Normalized name: Danvatirsen
DrugBank: Danvatirsen (DB14825)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danvatirsen 3 mg/kg
Study: 30661177
Drug: Danvatirsen 200
Normalized name: Danvatirsen
DrugBank: Danvatirsen (DB14825)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danvatirsen 200 mg flat dosing
Study: 30661177
Drug: Flat dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat dosing regimen
Study: 30662958
Drug: Individual rewards
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual rewards for diabetes management, details on dosage and duration not available.
Study: 30662958
Drug: Mixed rewards
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed rewards for diabetes management, details on dosage and duration not available.
Study: 30664483
Drug: Ghya Bharari
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghya Bharari Ekatra intervention delivered in 6 weekly sessions by trained community educators; includes games, discussions, self-reflections, and skill-building exercises.
Study: 30664496
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with TheraSphere yttrium-90 (TARE)
Study: 30664564
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 1 g/kg/dose infused at 3-5, 30, and 60 days post-hepatoportoenterostomy (HPE)
Study: 30667281
Drug: Evidence-based acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based acute treatments for ACS (including early dual antiplatelet therapy, heparins during hospitalization, reperfusion therapy for ST-segment-elevation myocardial infarction)
Study: 30667281
Drug: Strategies for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategies for secondary prevention (including dual antiplatelet therapy, ACE inhibitors/ARBs, statins at discharge, smoking cessation, cardiac rehabilitation counseling)
Study: 30667348
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of anticoagulation therapy after endovascular thrombus removal and stent placement
Study: 30668217
Drug: DTaP-IPV vaccine
Normalized name: DTaP-IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV vaccine
Study: 30668843
Drug: Early therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early therapy (ET) - HIV-1-infected children
Study: 30668843
Drug: Late therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late therapy (LT) - HIV-1-infected children
Study: 30670069
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (72.3%)
Study: 30670069
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents (72.3%)
Study: 30671005
Drug: Brief psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychological treatment based on Unified Protocol (UP)
Study: 30671005
Drug: Conventional psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional psychological treatment
Study: 30671005
Drug: Conventional psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional psychological treatment plus pharmacological treatment
Study: 30671283
Drug: Mindfulness for
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness for Interdisciplinary HCPs (MIHP) - an 8-week, group-based course with weekly meditation training, gentle yoga, and discussions.
Study: 30662958
Drug: Individual rewards
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual rewards for diabetes management, details on dosage and duration not available
Study: 30662958
Drug: Mixed rewards
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed rewards for diabetes management, details on dosage and duration not available
Study: 30672136
Drug: Oral sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral sirolimus
Study: 30672141
Drug: PPI plus
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI plus histamine-2 (H2) blocker
Study: 30672141
Drug: Control (H2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (H2 blocker alone)
Study: 30673992
Drug: Avaxim (Hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avaxim (Hepatitis A Virus Vaccine)
Study: 30674731
Drug: 2 mg/d
Normalized name: Uceris, 2 mg/dose rectal foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/d oral nitisinone
Study: 30674905
Drug: MR-guided focused
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-guided focused ultrasound (MRgFUS) with systemically administered chemotherapy (liposomal doxorubicin or temozolomide)
Study: 30674905
Drug: MR-guided focused
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-guided focused ultrasound (MRgFUS) with systemically administered chemotherapy
Study: 30675234
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 mg/kg, q3w) with platinum-doublet chemotherapy for up to 6 cycles, followed by maintenance therapy for non-progressors
Study: 30675234
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 mg/kg, q3w) with platinum-doublet chemotherapy for up to 6 cycles, without maintenance therapy
Study: 30678470
Drug: Insulin balanced
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin balanced infusion system (IBIS)
Study: 30678753
Drug: Single-molecule counting
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-molecule counting high-sensitivity troponin I (hsTnI) with normal range <6 ng/l
Study: 30679288
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) at doses of 30, 40, 50, or 60 mg/kg as a loading dose followed by maintenance doses of a quarter of the loading dose every 8 hours.
Study: 30679332
Drug: Perineural dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural dexmedetomidine (1 mL dexmedetomidine 100 µg/mL + 4 mL ropivacaine 5 mg/mL)
Study: 30679332
Drug: Systemic dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic dexmedetomidine (1 mL saline + 4 mL ropivacaine 5 mg/mL)
Study: 30679332
Drug: Control (NoDex:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (NoDex: 1 mL saline + 4 mL ropivacaine 7.5 mg/mL)
Study: 30680407
Drug: Elbasvir 50
Normalized name: elbasvir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir 50 mg and Grazoprevir 100 mg once daily for 10 days
Study: 30680712
Drug: PF-06647263 administered
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06647263 administered every week (QW)
Study: 30680712
Drug: PF-06647263 administered
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06647263 administered every 3 weeks (Q3W)
Study: 30680712
Drug: PF-06647263 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06647263 at the recommended phase 2 dose (RP2D) of 0.015 mg/kg QW
Study: 30681551
Drug: CytoSorb treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CytoSorb treatment (2 consecutive 24-hour treatments)
Study: 30681793
Drug: ATX-101 (deoxycholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX-101 (deoxycholic acid injection)
Study: 30681798
Drug: High-intensity precision
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity precision RF and fractional laser therapy
Study: 30682081
Drug: Profile likelihood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profile likelihood based pointwise confidence intervals (CIs) for a nonlinear dose-response model.
Study: 30682081
Drug: Profile likelihood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profile likelihood based pointwise confidence intervals (CIs) for nonlinear dose-response models.
Study: 30683996
Drug: Previous immunisation
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous immunisation with 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Study: 30684076
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg daily for 24 weeks
Study: 30684309
Drug: Glibenclamide oral
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide oral suspension
Study: 30684505
Drug: Education-based intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education-based intensified insulin therapy (EBIIT)
Study: 30685808
Drug: G-CSF-primed haplo-identical
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF-primed haplo-identical HSCT (Haplo-ID)
Study: 30686583
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of oral cortisol (CORT)
Study: 30686586
Drug: mAb114 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb114 5 mg/kg
Study: 30686586
Drug: mAb114 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb114 25 mg/kg
Study: 30686586
Drug: mAb114 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb114 50 mg/kg
Study: 30686586
Drug: mAb114 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb114 (all doses)
Study: 30686676
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of PLX-PAD cells
Study: 30686756
Drug: Metformin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin added to abiraterone at 1000 mg twice daily in uninterrupted 4-week cycles
Study: 30686767
Drug: Lumacaftor 100
Normalized name: lumacaftor 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor 100 mg and ivacaftor 125 mg (bodyweight <14 kg) or lumacaftor 150 mg and ivacaftor 188 mg (bodyweight ≥14 kg) orally every 12 h for 15 days (part A) and for 24 weeks (part B)
Study: 30687117
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no curry or lower doses)
Study: 30687508
Drug: Invasive coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive coronary artery function-guided diagnosis and treatment
Study: 30687508
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no invasive coronary artery function-guided diagnosis and treatment)
Study: 30687714
Drug: Curcumin Phytosome
Normalized name: Jarrow Formulas Curcumin Phytosome Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin Phytosome (CP) 2 g/day for 2 weeks
Study: 30687792
Drug: MVA85A vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA85A vaccine, details on dosage and duration not available
Study: 30687970
Drug: IVIG 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 10% (1 g/kg daily)
Study: 30688008
Drug: Raltegravir-based regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir-based regimen (protease-inhibitor-free)
Study: 30688175
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and skills related to behavioral and psychological symptoms of dementia, disease expectations, safety, activities of daily living, medical care optimization, and medication utilization
Study: 30689042
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg/day for 26 weeks (rasagiline-rasagiline group)
Study: 30689042
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg/day for 26 weeks (placebo-rasagiline group)
Study: 30689735
Drug: Nimotuzumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (200 mg weekly) combined with cisplatin (100 mg/m2 D1) and 5-fluorouracil (4 g/m2 continuous infusion D1-4) every 3 weeks for a maximum of six cycles
Study: 30689735
Drug: Nimotuzumab (≥2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (≥2400 mg) and ≥4 cycles of PF
Study: 30689735
Drug: Nimotuzumab-PF chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab-PF chemotherapy
Study: 30691339
Drug: Prior warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior warfarin treatment with INR <2
Study: 30691339
Drug: Prior warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior warfarin treatment with INR ≥2
Study: 30691536
Drug: Enadenotucirev monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enadenotucirev monotherapy
Study: 30691827
Drug: Ductal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ductal lavage with intraductal infusion of corticosteroids and antimicrobial agents, followed by breast massage for 2 weeks.
Study: 30692121
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg daily plus palbociclib 100 mg on days 1 to 21 of each 28-day cycle
Study: 30693097
Drug: Psychoeducational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational group treatment
Study: 30696370
Drug: Sufficient iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufficient iodine intake (188 μg/day [145-235 μg/day])
Study: 30696422
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-testing kit
Study: 30696669
Drug: Escalation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation of controller therapy during visits
Study: 30697903
Drug: Ceritinib (second-generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceritinib (second-generation ALK inhibitor)
Study: 30698644
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus lenalidomide (R2); Rituximab 375/m2 i.v. on Day 1; Lenalidomide 20 mg/day (Day 1-21 for cycle 1), 25 mg/day (Day 1-21 for subsequent cycles); followed by maintenance of lenalidomide 10 mg/day for 12 cycles.
Study: 30700568
Drug: Olaparib 150
Normalized name: olaparib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 150 mg tablet twice daily combined with metronomic carboplatin AUC2 and paclitaxel 60 mg/m2
Study: 30700614
Drug: Postdischarge chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postdischarge chemotherapy
Study: 30700726
Drug: Fresh mother's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh mother's own milk once daily from enrollment until 32 weeks' corrected age
Study: 30703787
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy after high-quality cytoreductive surgery (CRS)
Study: 30703787
Drug: Hyperthermic intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin
Study: 30703787
Drug: NCT03026140 study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NCT03026140 study on neoadjuvant treatment for early tumors
Study: 30703787
Drug: New targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: New targeted drugs (Eltanexor and cobimetinib)
Study: 30704447
Drug: Push mechanisms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Push mechanisms (e.g. poor health, poor working environment, age discrimination)
Study: 30704447
Drug: Stay mechanisms
Normalized name: benzalkonium chloride Topical Foam [Stay Clean]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stay mechanisms (e.g. attractive working conditions, good working environment)
Study: 30705758
Drug: Radiprodil oral
Normalized name: Radiprodil
DrugBank: Radiprodil (DB12260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiprodil oral suspension (30 mg, 12 mL)
Study: 30706431
Drug: Delayed-release dimethyl
Normalized name: dimethyl fumarate Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release dimethyl fumarate (DMF) with GI management strategies
Study: 30706431
Drug: Counseling about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling about GI events and recommendations for DMF administration
Study: 30706431
Drug: Symptomatic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapies for GI AEs
Study: 30706490
Drug: Twice-weekly prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly prednisolone (5 mg/kg/dose)
Study: 30706561
Drug: Residents with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residents with psychosis without antipsychotic medication
Study: 30708264
Drug: T-DM1 (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DM1 (3.6 mg/kg every 3 weeks)
Study: 30709364
Drug: Intrathecal delivery
Normalized name: Intrathecal Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal delivery of a viral vector in a Phase I gene therapy clinical trial for GAN.
Study: 30709417
Drug: Alerts regarding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alerts regarding potentially inappropriate DOAC doses
Study: 30709417
Drug: Alerts regarding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alerts regarding potentially inappropriate concomitant antiplatelet agents
Study: 30709417
Drug: Alerts regarding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alerts regarding other drug related problems
Study: 30709431
Drug: Ublituximab (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ublituximab (900 mg IV), Umbralisib (800 mg orally once daily), Ibrutinib (420 mg for CLL, 560 mg for NHL)
Study: 30709431
Drug: Ublituximab, Umbralisib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ublituximab, Umbralisib, and Ibrutinib combination
Study: 30710527
Drug: Treg cells
Normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treg cells incubated with rapamycin and RARA agonist (RAR568)
Study: 30711772
Drug: BAY 1238097
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1238097 at 10 mg/week
Study: 30711772
Drug: BAY 1238097
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1238097 at 40 mg/week
Study: 30711772
Drug: BAY 1238097
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1238097 at 80 mg/week
Study: 30711772
Drug: BAY 1238097
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1238097 (all doses)
Study: 30713028
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma vitamin E levels with high selenium levels (median≥83.7 μg/L)
Study: 30713028
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma vitamin E levels with low selenium levels (<83.7 μg/L)
Study: 30713498
Drug: Rituximab (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (initially at a low dose of 150 mg/m2)